Organon announced on July 7, 2025, that VTAMA (tapinarof) cream, 1%, received a strong recommendation from the American Academy of Dermatology (AAD) in their updated 2025 guidelines for the management of adults with moderate to severe atopic dermatitis (AD). This recommendation highlights VTAMA cream as an effective, steroid-free option for daily disease management.
The AAD's strong evidence-based recommendation is based on data from the ADORING 1 and ADORING 2 8-week clinical trials. VTAMA cream has no label warnings or precautions, no contraindications, and no restrictions on duration of use or percentage of body surface area affected.
This strong recommendation, combined with findings from the Phase 3 ADORING 3 long-term extension study showing a treatment-free interval lasting an average of 80 days after treatment success, positions VTAMA cream to redefine the AD treatment landscape and provide lasting results for patients.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.